Microviable Therapeutics SL
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Microviable Therapeutics SL - overview
Established
2016
Location
-, -, Spain
Primary Industry
Biotechnology
About
Founded in 2016 and based in Asturias, Spain, Microviable Therapeutics SL operates as a biotechnology company. In April 2022, Microviable Therapeutics SL raised EUR 1. 5 million in seed funding led by new investor Inmunomet Intolerancia y Disbiosis SL. The company was founded by Claudio Cantabrana, Noelia Martinez Alvarez, Abelardo Margolles, and Borja Sánchez.
Microviable Therapeutics SL develops biotherapeutic products and provides services such as microbiota analyses which involves analyses of the composition and functionality of the intestinal microbiota; microbiota storage which involves storing intestinal microbiota in viable conditions; and biotherapeutics development through the product GutAlive®. The company plans to use the funding to improve its medicinal research platform and move its pipeline closer to clinical trials.
Current Investors
Inmunomet Intolerancia y Disbiosis SL.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.microviable.com
Verticals
Manufacturing
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Microviable Therapeutics SL - timeline of key events
Microviable Therapeutics SL - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue (USD) | 5,208.8 | 46,186.3 | 15,050.3 | 80,368 | - | - | - |
| % Revenue Growth (YoY) | - | 786.7% | (67.4%) | 434.0% | - | - | - |
| EBITDA (USD) | 6,567.6 | (2,460.5) | (159,175.6) | (125,902.6) | - | - | - |
| Operating Income (USD) | 4,179 | (17,179.7) | (174,447.6) | (142,652.1) | - | - | - |
| Operating Margin | 80.2% | (37.2%) | (1159.1%) | (177.5%) | - | - | - |
| % EBITDA Margin | 126.1% | (5.3%) | (1057.6%) | (156.7%) | - | - | - |
| NET Income (USD) | 3,443.6 | (13,130.8) | (132,801.4) | (102,667.5) | - | - | - |
| % Net Margin | 66.1% | (28.4%) | (882.4%) | (127.7%) | - | - | - |
Microviable Therapeutics SL - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Seed | Completed | Microviable Therapeutics SL | - |
Displaying 1 - 1 of 1
Microviable Therapeutics SL - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.